Citius Pharmaceuticals, Inc. (CTXR) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001506251 · SEC filings checked Oct 17, 2026
Next report
Nov 13, 2026
Estimated from reporting history (91-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
Last close
$0.46
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
$-1.68
Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 14, 2026 | $1.5M | — | $-0.34 | Filing |
| Mar 31, 2026 | May 15, 2026 | $1.7M | — | $-0.95 | Filing |
| Dec 31, 2025 | Feb 13, 2026 | $3.9M | — | $-0.38 | Filing |
| Sep 30, 2025 | Dec 23, 2025 | — | — | $-0.01 | Filing |
| Jun 30, 2025 | Aug 12, 2025 | — | — | $-0.80 | Filing |
| Mar 31, 2025 | May 14, 2025 | — | $-11.5M | $-1.27 | Filing |
| Dec 31, 2024 | Feb 14, 2025 | — | $-10.3M | $-1.30 | Filing |
| Sep 30, 2024 | Dec 27, 2024 | — | — | $-1.61 | Filing |
What would Citius Pharmaceuticals, Inc. have to report for its valuation to change?
Trailing earnings are negative, so a price-to-earnings reverse model does not apply. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.